Comparative Analysis of The Effectiveness of Antihypertensive Therapy Including Spironolactone and Eplerenone in Patients With Essential Hypertension and Atrial Fibrillation

Aim. To perform a comparative analysis of the efficacy of antihypertensive therapy (AHT) containing spironolactone or eplerenone in patients with essential arterial hypertension (AH) and atrial fibrillation (AF).

Material and methods. The study included 99 male and female patients with essential AH complicated by permanent AF, who were receiving the outpatient treatment at the National Specialized Scientific and Practical Medical Center of Cardiology (Tashkent). The patients aged 61.3±9.5 years, the mean duration of AH was 12.9±8.3 years. All patients were divided into two groups: Group 1, patients who completed a 6-month combination AHT containing spironolactone (n=51); Group 2, patients who completed a 6-month combination AHT containing eplerenone (n=48). AF was diagnosed by electrocardiogram (ECG) and/or 24-hour ECG monitoring according to standard diagnostic criteria. The ECG study was performed in compliance with the American Society of Echocardiography Guidelines in M- and B-modes. The degree of structural vascular alterations was determined by the intima-media thickness of the common carotid artery by duplex scanning and microalbuminuria in morning urine. The concentrations of sex hormones were measured by the enzyme immunoassay. The serum concentrations of lipids, glucose, creatinine, and uric acid were measured by the enzymatic method. The glomerular filtration rate (GFR) was calculated with the EPI formula. Results of all studies were considered statistically significant at p<0.05.

Results. The proportion of patients who achieved the target diastolic blood pressure (BP) values was significantly greater in the eplerenone-containing treatment group than in the spironolactone-containing treatment group: 87.8% vs. 67.5% (p=0.043). The proportion of patients who simultaneously achieved the target systolic and diastolic BP values was slightly greater in the eplerenone-containing treatment group than in the spironolactone-containing group (100% vs. 92.1%, p=0.060). The best cardioprotective efficacy was observed in the group of combination AHT containing eplerenone. Specifically, in Group 2, the left ventricular ejection fraction (LVEF) was significantly improved compared to Group 1: from 55.4±10.6% at baseline to 52.6±9.1% in Group 1 (p>0.05) and from 54.8±8.8% at baseline to 58.2±6.4% in Group 2 (p<0.02). Only in Group 2, the left atrial volume index (LAVI) was significantly decreased compared to Group 1. Thus, in Group 1, the LAVI changed from 42.2±15.1 ml/m² at baseline to 40.4±12.2 ml/m² (p>0.05) and in Group 2, from 41.2±15.3 ml/m² at baseline to 37.3±13.5 ml/m² after the treatment (p<0.05); the ∆% LAVI in the eplerenone group was -5.9% vs. -0.36% in the spironolactone group. In men of Group 1, estradiol significantly increased from 13.9±12.6 pmol/l at baseline to 22.7±12.4 pmol/l (p<0.001).

Conclusion. The good antihypertensive efficacy of the 6-month combination therapy containing eplerenone was significantly superior to spironolactone in achieving the target BP values. The eplerenone-containing treatment significantly improved LVEF and decreased LAVI compared to the spironolactone-containing treatment. A trend towards a beneficial effect of the AHT containing eplerenone on concentrations of sex hormones was noted in both women and men.

1. Zhou B, Carrillo-Larco RM, Danaei G, Riley LM, Paciorek CJ, Stevens GA et al. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. The Lancet. 2021;398(10304):957–80. DOI: 10.1016/S0140-6736(21)01330-1

2. World Health Organisation. Prevalence of risk factors for noncommunicable diseases in the Republic of Uzbekistan, 2019. Av. at: https://www.who.int/europe/publications/i/item/WHO-EURO-2022-6795-46561-67569.

3. Benetos A, Petrovic M, Strandberg T. Hypertension Management in Older and Frail Older Patients. Circulation Research. 2019;124(7):1045–60. DOI: 10.1161/CIRCRESAHA.118.313236

4. Ji H, Kim A, Ebinger JE, Niiranen TJ, Claggett BL, Bairey Merz CN et al. Sex Differences in Blood Pressure Trajectories Over the Life Course. JAMA Cardiology. 2020;5(3):19–26. DOI: 10.1001/jamacardio.2019.5306

5. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285(18):2370–5. DOI: 10.1001/jama.285.18.2370

6. Van Gelder IC, Crijns HJ, Tieleman RG, Brugemann J, De Kam PJ, Gosselink AT et al. Chronic atrial fibrillation. Success of serial cardioversion therapy and safety of oral anticoagulation. Archives of Internal Medicine. 1996;156(22):2585–92. DOI: 10.1001/archinte.156.22.2585

7. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Russian Journal of Cardiology. 2021;26(9):234–329. DOI: 10.15829/1560-4071-2021-4701

8. Go O, Rosendorff C. Hypertension and atrial fibrillation. Current Cardiology Reports. 2009;11(6):430–5. DOI: 10.1007/s11886-009-0062-4

9. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary. Journal of the American College of Cardiology. 2022;79(17):1757–80. DOI: 10.1016/j.jacc.2021.12.011

10. Bozkurt B, Coats AJ, Tsutsui H, Abdelhamid M, Adamopoulos S, Albert N et al. Universal Definition and Classification of Heart Failure: A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. Journal of Cardiac Failure. 2021;27(4):387–413. DOI: 10.1016/j.cardfail.2021.01.022

11. Liu PY, Death AK, Handelsman DJ. Androgens and Cardiovascular Disease. Endocrine Reviews. 2003;24(3):313–40. DOI: 10.1210/er.2003-0005

12. English K, Mandour O, Steeds RP, Diver MJ, Jones TH, Channer KS. Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. European Heart Journal. 2000;21(11):890–4. DOI: 10.1053/euhj.1999.1873

13. English KM, Steeds R, Jones TH, Channer KS. Testosterone and coronary heart disease: is there a link? QJM. 1997;90(12):787–91. DOI: 10.1093/qjmed/90.12.787

14. Dubey RK, Tofovic SP, Jackson EK. Cardiovascular Pharmacology of Estradiol Metabolites. Journal of Pharmacology and Experimental Therapeutics. 2004;308(2):403–9. DOI: 10.1124/jpet.103.058057

15. Zeller T, Schnabel RB, Appelbaum S, Ojeda F, Berisha F, Schulte-Steinberg B et al. Low testosterone levels are predictive for incident atrial fibrillation and ischaemic stroke in men, but protective in women – results from the FINRISK study. European Journal of Preventive Cardiology. 2018;25(11):1133–9. DOI: 10.1177/2047487318778346

16. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. European Heart Journal. 2021;42(5):373–498. DOI: 10.1093/eurheartj/ehaa612

17. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation. 1978;58(6):1072–83. DOI: 10.1161/01.CIR.58.6.1072

18. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation. 1977;55(4):613–8. DOI: 10.1161/01.CIR.55.4.613

19. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal. 2018;39(33):3021–104. DOI: 10.1093/eurheartj/ehy339

20. Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B et al. Effects of Eplerenone, Enalapril, and Eplerenone/Enalapril in Patients With Essential Hypertension and Left Ventricular Hypertrophy: The 4E–Left Ventricular Hypertrophy Study. Circulation. 2003;108(15):1831–8. DOI: 10.1161/01.CIR.0000091405.00772.6E

21. Deinum J, Riksen NP, Lenders JWM. Pharmacological treatment of aldosterone excess. Pharmacology & Therapeutics. 2015;154:120–33. DOI: 10.1016/j.pharmthera.2015.07.006

22. Pardo-Martínez P, Barge-Caballero E, Bouzas-Mosquera A, Barge-Caballero G, Couto-Mallón D, Paniagua-Martín MJ et al. Real world comparison of spironolactone and eplerenone in patients with heart failure. European Journal of Internal Medicine. 2022;97:86–94. DOI: 10.1016/j.ejim.2021.12.027

23. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B et al. Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction. New England Journal of Medicine. 2003;348(14):1309–21. DOI: 10.1056/NEJMoa030207

24. Swedberg K, Zannad F, McMurray JJV, Krum H, van Veldhuisen DJ, Shi H et al. Eplerenone and Atrial Fibrillation in Mild Systolic Heart Failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization and SurvIval Study in Heart Failure) study. Journal of the American College of Cardiology. 2012;59(18):1598–603. DOI: 10.1016/j.jacc.2011.11.063

25. Vukadinović D, Lavall D, Vukadinović AN, Pitt B, Wagenpfeil S, Böhm M. True rate of mineralocorticoid receptor antagonists-related hyperkalemia in placebo-controlled trials: A meta-analysis. American Heart Journal. 2017;188:99–108. DOI: 10.1016/j.ahj.2017.03.011

26. Iqbal J, Parviz Y, Pitt B, Newell-Price J, Al-Mohammad A, Zannad F. Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failure. European Journal of Heart Failure. 2014;16(2):143–50. DOI: 10.1111/ejhf.31

27. Lainscak M, Pelliccia F, Rosano G, Vitale C, Schiariti M, Greco C et al. Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone. International Journal of Cardiology. 2015;200:25–9. DOI: 10.1016/j.ijcard.2015.05.127

28. Jankowska EA, Biel B, Majda J, Szklarska A, Lopuszanska M, Medras M et al. Anabolic Deficiency in Men With Chronic Heart Failure: Prevalence and Detrimental Impact on Survival. Circulation. 2006;114(17):1829–37. DOI: 10.1161/CIRCULATIONAHA.106.649426

29. Sica DA. The risks and benefits of aldosterone antagonists. Current Heart Failure Reports. 2005;2(2):65–71. DOI: 10.1007/s11897-005-0011-5

30. Naser N, Nalbantic A, Nalbantic N, Karic A. The Effectiveness of Eplerenone vs Spironolactone on Left Ventricular Systolic Function, Hospitalization and Cardiovascular Death in Patients With Chronic Heart Failure–HFrEF. Medical Archives. 2023;77(2):105–11. DOI: 10.5455/medarh.2023.77.105-111